Abivax ABVX
NASDAQ ABVX
$114.61 +0.57 (+0.50%)
As of: Sep 4, 2026 · 12:46 PM EDT

Abivax (ABVX) Non Operating Interest Expenses (2024 - 2026)

Analysis

Abivax (ABVX) Non Operating Interest Expenses (2024 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Vertex Pharmaceuticals 139.76 Bn 131.91 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.72 Bn 77.72 Bn 3.93 Bn 11.00 Mn
3 Argenx Se 63.56 Bn 58.38 Bn 1.37 Bn -1.00 Mn
4 Moderna 57.87 Bn 52.73 Bn 52.00 Mn -
5 Revolution Medicines 44.06 Bn 44.06 Bn - 23.78 Mn
6 BeOne Medicines 40.08 Bn 34.98 Bn 1.53 Bn 39.74 Mn
7 Alnylam Pharmaceuticals 35.50 Bn 32.20 Bn 992.69 Mn 82.05 Mn
8 Royalty Pharma 28.54 Bn 27.70 Bn - 93.62 Mn
9 Insmed 27.49 Bn 26.33 Bn 358.27 Mn 20.27 Mn
10 Abivax 8.00 Bn 8.00 Bn - -5.58 Mn
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 -5.58 Mn
Dec 31, 2025 -10.78 Mn
Sep 30, 2025 -108.78 Mn
Jun 30, 2025 -6.13 Mn
Mar 31, 2025 -7.07 Mn
Dec 31, 2024 -388,968.73
Sep 30, 2024 -9.31 Mn
Jun 30, 2024 -7.60 Mn
Mar 31, 2024 -4.59 Mn